Litcius/Paper detail

Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP)

Antonio Passaro, Giuseppe Lo Russo, Francesco Passiglia, M. D’Arcangelo, Andrea Sbrana, Marco Russano, Laura Bonanno, Raffaele Giusti, Giulio Metro, Federica Bertolini, Salvatore Grisanti, Annamaria Carta, Fabiana Letizia Cecere, Michele Montrone, Giacomo Massa, Fabiana Perrone, Francesca Simionato, Giorgia Guaitoli, Vieri Scotti, Carlo Genova, Antonio Lugini, Lucia Bonomi, Ilaria Attili, Filippo de Marinis

2022Lung Cancer12 citationsDOI

Topics & Concepts

MedicineInternal medicineConfidence intervalOncologyLung cancerPopulationAdverse effectFusion geneExpanded accessRetrospective cohort studyChemotherapyClinical trialGastroenterologyGeneChemistryBiochemistryEnvironmental healthLung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersLung Cancer Research Studies
Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP) | Litcius